TY - JOUR
TI - Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial
AU - Poveda, A.M.
AU - Selle, F.
AU - Hilpert, F.
AU - Reuss, A.
AU - Savarese, A.
AU - Vergote, I.
AU - Witteveen, P.
AU - Bamias, A.
AU - Scotto, N.
AU - Mitchell, L.
AU - Pujade-Lauraine, E.
JO - Journal of Clinical Oncology
PY - 2015
VL - 33
TODO - 32
SP - 3836-3838
PB - American Society of Clinical Oncology
SN - 0732-183X, 1527-7755
TODO - 10.1200/JCO.2015.63.1408
TODO - bevacizumab;  doxorubicin;  paclitaxel;  topotecan;  antineoplastic agent;  bevacizumab;  doxorubicin;  macrogol derivative;  paclitaxel;  platinum derivative;  topotecan, adult;  aged;  cancer combination chemotherapy;  cancer diagnosis;  cancer recurrence;  cancer resistance;  controlled study;  female;  human;  intention to treat analysis;  Letter;  major clinical study;  open study;  outcome assessment;  ovary cancer;  overall survival;  phase 3 clinical trial;  platinum resistant recurrent ovarian cancer;  priority journal;  progression free survival;  quality of life;  randomized controlled trial;  analogs and derivatives;  cancer grading;  cancer staging;  clinical trial;  drug administration;  drug resistance;  Kaplan Meier method;  middle aged;  Ovarian Neoplasms;  pathology;  prognosis;  risk factor;  treatment outcome;  tumor recurrence;  very elderly, Adult;  Aged;  Aged, 80 and over;  Antineoplastic Combined Chemotherapy Protocols;  Bevacizumab;  Doxorubicin;  Drug Administration Schedule;  Drug Resistance, Neoplasm;  Female;  Humans;  Kaplan-Meier Estimate;  Middle Aged;  Neoplasm Grading;  Neoplasm Recurrence, Local;  Neoplasm Staging;  Ovarian Neoplasms;  Paclitaxel;  Platinum Compounds;  Polyethylene Glycols;  Prognosis;  Risk Factors;  Topotecan;  Treatment Outcome
TODO - null
ER -